Hassan Y. Farhat

Internal Medicine

160 NW 170th St
North Miami Beach, FL 33169

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Bedside Ultrasound-Guided Innominate Vein Cannulation for Central Line Placement in Newborns.

Bedside Ultrasound-Guided Innominate Vein Cannulation for Central Line Placement in Newborns.

Journal: Journal of pediatric surgery

Published: February 17, 2025

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Journal: Blood advances

Published: January 02, 2025

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 16, 2024

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.

Journal: Haematologica

Published: September 17, 2021

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 14, 2021

Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review.

Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review.

Journal: EJHaem

Published: June 15, 2020

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Journal: The Lancet. Oncology

Published: September 13, 2018

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Journal: Leukemia

Published: February 04, 2018

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Journal: Leukemia & lymphoma

Published: November 29, 2017

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity.

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity.

Journal: Annales de cardiologie et d'angeiologie

Published: December 15, 2016

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

Journal: The Lancet. Haematology

Published: September 09, 2016

The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients.

The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients.

Journal: Infection control and hospital epidemiology

Published: June 25, 2016

Showing 1-12 of 16

Last Updated: 09/26/2026